Trial Profile
A Study to Determine Enzalutamide Long-term Safety and Efficacy After Anti-androgen Therapy for CRPC
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms DELC
- 18 Feb 2023 Results (between January 2016 and March 2019) assessing the long term safety, efficacy and prognostic factors in castration-resistant prostate cancer patients treated with enzalutamide, presented at the 2023 Genitourinary Cancers Symposium.
- 25 Dec 2022 Status changed from active, no longer recruiting to completed.
- 18 Jun 2019 Planned End Date changed from 1 Mar 2020 to 1 Mar 2021.